# SAD Study of CGB3002 in Healthy Participants

> **NCT07660341** · PHASE1 · RECRUITING · sponsor: **ChainGen Biopharma Ltd** · enrollment: 46 (estimated)

## Conditions studied

- Alzheimer s Disease

## Interventions

- **DRUG:** CGB3002 0.08 mg/kg
- **DRUG:** CGB3002 0.4 mg/kg
- **DRUG:** CGB3002 1.2 mg/kg
- **DRUG:** CGB3002 3.6 mg/kg
- **DRUG:** CGB3002 7.2 mg/kg
- **DRUG:** Placebo
- **DRUG:** Comparator Drug

## Key facts

- **NCT ID:** NCT07660341
- **Lead sponsor:** ChainGen Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660341, "SAD Study of CGB3002 in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*